Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 3/20 | 0.33 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | IL1B | P01584 | 1/20 | 0.30 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21932896 | 0.84 | IKZF2 (0.42) | IKZF2IKZF1CRBNDDB1BRD4 | |
| SCHEMBL21932889 | 0.84 | — | — | |
| SCHEMBL21932917 | 0.79 | CRBN (0.52) | IKZF2IKZF1CRBNDDB1BRD4 | |
| SCHEMBL22000914 | 0.78 | CRBN (0.51) | IKZF2IKZF1CRBNDDB1BRD4 | |
| SCHEMBL22000761 | 0.78 | CRBN (0.51) | IKZF2IKZF1CRBNDDB1BRD4 | |
| SCHEMBL22000917 | 0.77 | CRBN (0.52) | IKZF2IKZF1CRBNDDB1BRD4 | |
| SCHEMBL22018440 | 0.76 | TP53 (0.30) | — | |
| SCHEMBL30270636 | 0.74 | CRBN (0.54) | IKZF2IKZF1CRBNDDB1BRD4 | |
| SCHEMBL22000915 | 0.74 | CRBN (0.54) | IKZF2IKZF1CRBNDDB1BRD4 | |
| SCHEMBL28625447 | 0.74 | HTR2C (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352338-B2 | Substituted isoindolinones | BIOTHERYX, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352338-B2 | Substituted isoindolinones | BIOTHERYX, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-10844039-B2 | Substituted isoindolinones | BIOTHERYX, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10844039-B2 | Substituted isoindolinones | BIOTHERYX, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200325114-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| US-20200325114-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. (US) | 2020-10-15 | — | — | US | disclosed |
| WO-2020102195-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200148663-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20200148663-A1 | SUBSTITUTED ISOINDOLINONES | BIOTHERYX, INC. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148663-A1 | SUBSTITUTED ISOINDOLINONES | BRCA1, FANCI, GOT2 | IKZF2 1884/4885IKZF1 413/4885CRBN 1873/4885 |
| US-10844039-B2 | Substituted isoindolinones | BRCA1, FANCI, GOT2 | IKZF2 1884/4885IKZF1 413/4885CRBN 1873/4885 |
| US-20200325114-A1 | SUBSTITUTED ISOINDOLINONES | BRCA1, FANCI, GOT2 | IKZF2 1884/4885IKZF1 413/4885CRBN 1873/4885 |
| US-11352338-B2 | Substituted isoindolinones | BRCA1, FANCI, GOT2 | IKZF2 1884/4885IKZF1 413/4885CRBN 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.